Prostate Cancer

The data come just days after the FDA approved IsoPSA to aid in the diagnosis of high-grade prostate cancer.

For micro-ultrasound compared with true cancer status, estimated sensitivity was 0.8000.

The group discussed wide variation in when and how patients transition from urology to medical oncology.

At a median follow-up of 25.8 months, the CR rate at any time was 75.5%.

The investigators reported that new onset of CNS-related conditions was lower in patients in the apalutamide cohort at 12 months and 24 months post index.

Clinicians noted that symptoms—bone pain, declining function, anemia, and renal compromise—carry significant weight when choosing therapy.

The approval is supported by 12-month data from the prospective VAPOR 2 trial.

A recap of the FDA submissions and regulatory decisions in urology from November 2025.

The test is intended to aid in the decision for prostate biopsy in men aged 50 years or older who present with elevated PSA levels.

According to the authors, the optimal duration of treatment could be tied to individual patient factors such as cancer risk.

The clearance supports new ultrasound imaging and workflow enhancements to the Focal One i, which was launched earlier this year.

The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.

A major portion of the discussion focused on selecting among ARPIs for use with ADT in the mCSPC setting.

Jason M. Hafron, MD, CMO, touches on the growing shift toward biomarker-driven therapy in advanced prostate cancer.

Jason M. Hafron, MD, recaps noteworthy prostate cancer research from ESMO 2025.

Stacy Loeb, MD, discussed key takeaways from the European Randomized Study of Screening for Prostate Cancer.

Stacy Loeb, MD, shares key takeaways from her LUGPA 2025 session, “Current state of prostate cancer screening.”

Beyond radioligands, Henderson points to a number of novel therapeutic categories under investigation.

Henderson emphasized the evolving role of advanced biomarkers in refining prostate cancer risk assessment beyond traditional PSA testing

The phase 1b trial is assessing ORIC-944 both in combination with darolutamide and apalutamide.

Collins stresses the oncological importance of local control, as local recurrences can lead to a "second wave of metastatic disease" that can ultimately cause death.

Alice Bernard-Tessier, MD, highlights preliminary results from a phase 1 trial of gedatolisib plus darolutamide in mCRPC.

"I think MRI has really been perhaps the most transformative development in the realm of prostate cancer screening since I came into the field," says Stacy Loeb, MD, MSc, PhD (Hon.

"It's been a very exciting time for the radioligand space," says J. Travis Mendel, MD.

The rectal spacer showed sustained preservation of bowel, urinary, and sexual quality of life through 4 years of follow-up.